Insider Selling: Dyadic International (NASDAQ:DYAI) Major Shareholder Sells 20,000 Shares

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 20,000 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $1.92, for a total value of $38,400.00. Following the sale, the insider owned 3,390,664 shares in the company, valued at approximately $6,510,074.88. This trade represents a 0.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Dyadic International Stock Performance

Dyadic International stock opened at $0.94 on Monday. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. The stock has a fifty day moving average of $0.77 and a two-hundred day moving average of $0.83. The company has a market capitalization of $34.27 million, a price-to-earnings ratio of -4.09 and a beta of 1.15. Dyadic International Inc. has a fifty-two week low of $0.65 and a fifty-two week high of $1.35.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The company had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. On average, analysts anticipate that Dyadic International Inc. will post 0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Marathon Capital Management purchased a new position in shares of Dyadic International during the 3rd quarter worth $41,000. Bank of America Corp DE grew its position in shares of Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the period. Landscape Capital Management L.L.C. purchased a new stake in shares of Dyadic International in the third quarter valued at $190,000. Geode Capital Management LLC increased its stake in Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares during the last quarter. Finally, Apis Capital Advisors LLC acquired a new position in Dyadic International in the third quarter valued at $1,817,000. 27.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Dyadic International has an average rating of “Hold” and a consensus target price of $3.00.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.